For Immediate Release
Chicago, IL – October 07, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Costco (NASDAQ:(COST - Free Report) –Free Report),ExxonMobil (NYSE:(XOM - Free Report) –Free Report),Bristol-Myers (NYSE:(BMY - Free Report) – Free Report), Shire (NASDAQ:(SHPG - Free Report) –Free Report) and Darden (NYSE:(DRI - Free Report) – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Costco, Exxon, Bristol Myers
Today's Research Daily features new research reports on 16 major stocks, including Costco (NASDAQ:(COST - Free Report) – Free Report), ExxonMobil (NYSE:(XOM - Free Report) – Free Report) and Bristol-Myers (NYSE:(BMY - Free Report) – Free Report).
Costco shares have been laggards lately as earnings performance has been weighed down by stiff competition and cautious consumer spending trends. However, the analyst emphasizes that Costco continues to be one of the dominant retail wholesalers based on its breadth and quality of merchandise offered. Also, the company’s diversification strategy acts as a natural hedge against risks that may arise in specific markets. (You can read the full research report on Pepsi here>>)
ExxonMobil shares have outperformed the broader market this year on the back oil's positive momentum, though the stock has lagged oil-ier super majors like Chevron and the major E&P's. This reflects the oil giant's balanced business mix that make it a relatively defensive oil play; the stock doesn't rise as much as its peers in a rising oil price environment, but it doesn't fall by that much when the commodity is heading south either. With a stable cash position, Exxon Mobil’s balance sheet is one of the best in the industry. Exxon's safe and stable dividend (currently yielding an attractive 3.5%) is another key positive. (You can read the full research report on ExxonMobil here>>)
Bristol-Myers shares have been depressed for some time now and are down 20% year-to-date. The company raised its guidance for 2016 earnings once again, buoyed by strong trends across the business, primarily Opdivo and Eliquis. The analyst likes Bristol-Myers’ efforts to develop its pipeline. It has been working on strengthening its product portfolio as well as its pipeline through acquisitions and deals. Also, Bristol-Myers is working on expanding the label of approved drugs including Opdivo, Orencia and Yervoy. (You can read the full research report on Bristol-Myers here>>)
Other noteworthy reports we are featuring today include Shire (NASDAQ:(SHPG - Free Report) –Free Report) and Darden (NYSE:(DRI - Free Report) – Free Report).
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
You can find all of today's stock research reports here>>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on COST - FREE
Get the full Report on XOM - FREE
Get the full Report on BMY - FREE
Get the full Report on SHPG - FREE
Get the full Report on DRI - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.